Translational Research Cancer Centers Consortium
The Translational Research Cancer Centers Consortium (TRCCC) was initiated in 1998 to expedite the progress in immunotherapy and other biologic therapies. The organization has successfully brought together leaders in this field to advance science, collaboration and clinical trials to help individuals diagnosed with cancer.
Seven Springs Mountain Resort
Seven Spring, Pennsylvania.
February 13-15, 2019.
The Cuban Center for Molecular Immunology (CIM) is an affiliate member of TRCCC. To explore new opportunities in Cancer Immunotherapy, TRCCC planning committee members and CIM investigators are holding a joint symposium to share information and discuss collaborations. Representatives of the American Association for the Advancement of Science (AAAS) and Dr. Sergio Pastrana, Executive Director and Secretary of Foreign Affairs of the Academy of Sciences of Cuba will attend and speak at the symposium. This is an exciting development in TRCCC.
Robert Vonderheide, an expert in cancer immunotherapy and translational research and member of TRCCC, was named director of the Abramson Cancer Center of the University of Pennsylvania. He is the Hanna Wise Professor in Cancer Research at the Perelman School of Medicine, and currently serves as the Abramson Cancer Center’s (ACC) associate director for translational research and executive director of its Translational Centers of Excellence Program. He will begin his new role on July 1. Through a focus on novel immunotherapies for pancreatic cancer, melanoma, breast and ovarian cancers, Vonderheide has mapped new models for speeding translational research. He has led studies that demonstrated the role of agonist CD40 antibodies, paving the way to ongoing late-stage clinical trials. His work on vaccine-based approaches for cancer treatment and prevention has been supported by the Abramson Family Cancer Research Institute and the Basser Center for BRCA. Vonderheide has also served among leaders of an interdisciplinary team which defined a promising therapy employing both radiation and immunotherapy drugs that together mount a vaccine-like attack against cancer cells in patients with advanced melanoma. His research has appeared in Nature, Science, Cell, the New England Journal of Medicine, and other leading medical journals. Vonderheide is also vice chair for research in the Division of Hematology-Oncology, and he serves as co-director of the Parker Institute for Cancer Immunotherapy at Penn. He is also co-leader of the Stand Up to Cancer— Lustgarten Foundation Pancreatic Cancer Convergence Dream Team.
At the 17th Annual Meeting of the American Society of Gene & Cell Therapy, Daniel J. Powell Jr., Ph.D., associate professor, Pathology and Laboratory Medicine, Abramson Cancer Center, was presented with The Outstanding New Investigator Award. The Outstanding New Investigator awards are presented to individuals whose early achievements in the field demonstrate remarkable distinction. Dr. Daniel Powell's important contributions to T cell-based cancer therapy include elucidation of the role of CD27 in human T cell memory, development of a novel dual signaling approach to CAR-T cell therapy to limit toxicity, and identification of CD137 as a marker of naturally occurring tumor-reactive T cells. Click here to read more.
Jonathan Powell, M.D., Ph.D.
Associate Director, Bloomberg~Kimmel Institute for Cancer Immunotherapy,
Professor of Oncology,
Johns Hopkins Medicine
The Translational Research Cancer Centers Consortium (TRCCC) mission is to gain a greater understanding of the interactions between the immune system and cancer in the setting of biologic therapy of cancer.